353 related articles for article (PubMed ID: 27480854)
1. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.
Jeong BH; Jeon K; Park HY; Moon SM; Kim SY; Lee SY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):6076-83. PubMed ID: 27480854
[TBL] [Abstract][Full Text] [Related]
2. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
[TBL] [Abstract][Full Text] [Related]
3. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
Am J Respir Crit Care Med; 2012 Oct; 186(8):797-802. PubMed ID: 22878282
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis.
Martiniano SL; Wagner BD; Brennan L; Wempe MF; Anderson PL; Daley CL; Anthony M; Nick JA; Sagel SD
J Cyst Fibros; 2021 Sep; 20(5):772-778. PubMed ID: 34030986
[TBL] [Abstract][Full Text] [Related]
7. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL
Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719
[TBL] [Abstract][Full Text] [Related]
9. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease.
Deshpande D; Pasipanodya JG; Gumbo T
Antimicrob Agents Chemother; 2016 Apr; 60(4):2157-63. PubMed ID: 26810646
[TBL] [Abstract][Full Text] [Related]
10. Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.
Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
Chest; 2024 May; 165(5):1058-1069. PubMed ID: 38086472
[TBL] [Abstract][Full Text] [Related]
11. Resumption/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen.
Kobayashi T; Tsuyuguchi K; Yoshida S; Kimura Y; Tsuji T; Minomo S; Kurahara Y; Inoue Y; Suzuki K
Respir Investig; 2021 Mar; 59(2):212-217. PubMed ID: 33436352
[TBL] [Abstract][Full Text] [Related]
12. Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic
Nakagawa T; Hashimoto H; Yagi M; Kogure Y; Sekimizu M; Saito AM; Ogawa K; Inoue Y
BMJ Open Respir Res; 2019; 6(1):e000434. PubMed ID: 31258920
[TBL] [Abstract][Full Text] [Related]
13. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease.
Lam PK; Griffith DE; Aksamit TR; Ruoss SJ; Garay SM; Daley CL; Catanzaro A
Am J Respir Crit Care Med; 2006 Jun; 173(11):1283-9. PubMed ID: 16514112
[TBL] [Abstract][Full Text] [Related]
14. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.
Jhun BW; Moon SM; Kim SY; Park HY; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203483
[TBL] [Abstract][Full Text] [Related]
15. Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.
Moon SM; Yoo IY; Huh HJ; Lee NY; Jhun BW
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611366
[TBL] [Abstract][Full Text] [Related]
16. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.
Griffith DE; Brown BA; Girard WM; Griffith BE; Couch LA; Wallace RJ
Clin Infect Dis; 2001 Jun; 32(11):1547-53. PubMed ID: 11340525
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
Koh WJ; Hong G; Kim SY; Jeong BH; Park HY; Jeon K; Kwon OJ; Lee SH; Kim CK; Shin SJ
Antimicrob Agents Chemother; 2013 May; 57(5):2281-5. PubMed ID: 23478956
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
Adachi Y; Tsuyuguchi K; Kobayashi T; Kurahara Y; Yoshida S; Kagawa T; Hayashi S; Suzuki K
J Infect Chemother; 2020 Jul; 26(7):676-680. PubMed ID: 32171660
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease.
Asakura T; Nakagawa T; Suzuki S; Namkoong H; Morimoto K; Ishii M; Kurashima A; Betsuyaku T; Ogawa K; Hasegawa N;
J Infect Chemother; 2019 Mar; 25(3):218-221. PubMed ID: 30172726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
